

[Open Peer Review on Qeios](#)

Inhibition Success of a Virtually Created Molecule: Pseudoeriocitrin and Femtomolar Inhibition

Dilara Karaman¹, Ahmet Onur Girişgin², Oya Girişgin²

¹ Yildiz Technical University

² Bursa Uludağ University

Funding: No specific funding was received for this work.

Potential competing interests: No potential competing interests to declare.

Abstract

Pseudoeriocitrin is a molecule that does not exist in reality but was created *in silico* by assuming the formation of oxygen radicals in eriocitrin and giving a different geometry. It gave femtomolar results during *in silico* docking studies being successful than eriocitrin in inhibition. This study investigated what might be the reason for this ability of pseudoeriocitrin, an unusual molecule with superior inhibitory activity. In this study, 3D analysis of possible interactions was performed using the *in silico* protein-ligand docking method. Although it is difficult to say anything definitive, the absence of hydrogen donors renders the pseudoeriocitrin structure highly toxic. This new molecule, which can inhibit various proteins at the femtomolar level, was predicted being responsible for high binding ability due to its planar large structure and lots of oxygen radicals which provides a number of hydrogen bonds with the atoms in the active site of the proteins. It is the first study to show the structure-activity relationship of pseudoeriocitrin via *in silico* dockings. In the result, it was shown that the large core structure, abundance of oxygen atoms, planar coordinates and femtomolar level inhibition were related. The chemical properties leading to these new biological properties should be considered from different angles, and more research should be conducted on the synthesis of non-radical pseudoeriocitrin.

Dilara KARAMAN^{1,a,*}, Ahmet Onur GİRİŞGİN^{2,b}, and Oya GİRİŞGİN^{3,c}

¹ Yildiz Technical University, Bioengineering Department, Istanbul-TÜRKİYE

² Bursa Uludağ University, Veterinary Faculty, Parasitology Department, Bursa-TÜRKİYE

³ Bursa Uludağ University, Karacabey Vocational School, Bursa-TÜRKİYE

ORCID iD: ^a0000-0003-4386-8531; ^b0000-0002-0020-2708, ^c0000-0001-9896-1093

***Corresponding author:** Dilara KARAMAN, e-mail: dilara.karaman@std.yildiz.edu.tr

Keywords: Eriocitrin, femtomolar inhibition, molecular docking, pseudoeriocitrin.

1. Introduction

In a world of technological advances where health services are rapidly evolving, helminth infections maintain their significance as a medical condition. According to 2012 data, approximately 2 billion people worldwide were infected with at least one species of helminth (World Health Organization [WHO], 2012). The frequent recurrence of infections among people living in areas with inadequate sanitation, and especially among preschool-aged children, increases the importance of alternative treatments to replace synthetic drugs. Therefore, the discovery of new anthelmintics with fewer side effects is a very important and challenging task. Oxyurid nematode infections, which are transmitted orally and recur frequently due to autoinfection, mostly occur in children and cause developmental disorders (Giray and Keskinoglu, 2006). It is estimated that 400 million people worldwide are infected with *Enterobius vermicularis* (Strelkauskas et al., 2015).

β -tubulin, carnitine o-palmitoyltransferase-2, and fumarate reductase are recently focused antinematodal targets for development of several anthelmintics such as albendazole, mebendazole, ivermectin and thiabendazole. Because the unknown genome sequence and the lack of crystallized structure of the proteins belonged to *Syphacia obvelata*, homology model of mitochondrial cytochrome c oxidase (COX) proteins can be useful for *in silico* docking experiments in order to investigate the antinematodal properties of some drug candidates against *S. obvelata* (Karaman, 2022).

Protein-ligand docking simulations performed by *in silico* molecular modeling are the first step towards drug development efforts, providing researchers with atomic-level data on target-drug interactions. Such computational experiments are of great importance in reducing the workload around drug development efforts.

Eriocitrin ((2S)-2-(3,4-dihydroxyphenyl)-5-hydroxy-7-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(((2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyl oxanyl-2]oxy)methyl)oxan-2-yl)oxy-chromen-4-yl) is one of the eriodictyol-derived flavonoid glycosides found mainly in lemon peel and citrus pulp and in plants such as thyme and mint (Inoue et al., 2002). It was formed by the addition of O- β -rutoside at the 7th position to eriodictyol. It has antioxidant, anti-inflammatory, and antiproliferative properties (Diab et al., 2015; Guo et al., 2019; Miyake et al., 1997). A study by Ferreira et al. reported the presence of eriocitrin and its metabolites in various organs and body fluids in rats administered orange peel extract. Homoeriodictyol and homo-eriodictyol-7-O-glucuronide are the major metabolites of homoeriodictyol, hesperetin and glucuronide metabolites. The half-life of metabolites in blood plasma ranges from 3 to 3.2 hours. Hesperetin-7-O- and hesperetin-3'-O-gluconic acid, metabolites of eriocitrin, were detected in both tissue and urine of rats. hERD-7O-Gluc reached approximately 8 ng/g in blood plasma 10 hours after administration, and hERD-4'-O-Gluc reached approximately 2 ng/g after 6 hours, the highest levels in blood. The gastrointestinal absorption of eriocitrin was very low and also that the total bioavailability of eriocitrin was less than 1% (Ferreira et al., 2021).

We investigated the anthelmintic effect of eriocitrin, whose molecular structure is shown in the following figure (Figure 1), in our previous study which yielded *in silico* outcomes (Karaman, 2022). Interestingly, it was found that there was an additional bond in the molecule when studying the possible interactions of eriocitrin with the proteins it inhibits. When this molecule, called pseudoeriocitrin, and its possible interactions were studied, it was found to inhibit several proteins at the femtomolar level ($K_f=10^{-17}$ mol/L). Pseudoeriocitrin has the same molecular weight, molecular formula, and atom types

with the eriocitrin. The only difference is an extra intramolecular bond between the C8 of chromene-4-on and oxygen atom of O- β -rutinoside.

The aim of this study was to show the structure and interactions of pseudoeriocitrin, to which it owes its very high score values, possibly related to its anthelmintic activity. First time a virtual molecule has been shown with femtomolar inhibition constants against several proteins. Hence its interactions with anthelmintic target proteins researched *in silico* are thoroughly new and original.




Figure 1. Rings forming eriocitrin (original). The bond leading to the formation of pseudoeriocitrin is formed between chromene-4-one ring and the oxygen atom of the hydroxyl group of the chromene-bonded monosaccharide of O- β -rutinoside.

2. Material and method

2.1. Obtaining and preparation of the ligand

Before one molecule showed anomalous binding in the docking studies, we retrieved the pdb file of this molecule from the FooDB database (www.foodb.ca) in November 2019 (ligand ID: FDB016547). In the pdb file of this molecule, which is registered in the FooDB database as eriocitrin, all Z coordinates were 0. We converted this pdb file to a pdbqt file using the AutoDock Tool (ADT) (Huey et al., 2007; Morris et al., 2009). When the Z coordinates were 0, the ADT program assumed bonding and ignored the hydrogen atom in the hydroxyl group because there was sufficient distance between the C8 atom in the chromene ring of the ligand and the oxygen atom of the hydroxyl group at the C3 position of the rutinoside group to allow bonding. The resulting pdbqt file lacked hydrogen donors.

2.2. Preparation of proteins

We studied proteins and enzymes that could be drug targets in nematodes. We used Biovia Discovery Studio 2020 Client (Dassault Systèmes Biovia Inc., 2020) and ADT software for protein preparation. For this purpose, we retrieved the target proteins and enzymes found in nematodes and their homologues in humans with their crystallized structures from the Brookhaven Protein Databank (<http://www.rcsb.org/pdb>). These proteins were as follows: *Ascaris suum* fumarate reductase enzyme PDB ID: 4YSX (mitochondrial rhodoquinol-fumarate reductase, solubility: 2.25 Å, bound with NN23 inhibitor) (Inaoka et al., 2015), human fumarate reductase enzyme PDB ID: 6VAX (resolution: 2.59 Å) (Sharma et al., 2020); human β -tubulin protein PDB ID: 6E7C (resolution: 3.65 Å) (Ti et al., 2018); *Haemonchus contortus* β -tubulin protein PDB ID: 1OJ0 (in complex with ABZ, theoretical structure) (Robinson et al., 2004); anthelmintic drug target rat carnitine o-palmitoyltransferase PDB ID: 2H4T (resolution: 1.90 Å, bound with dodecane (C₁₂H₂₆) (Hsiao et al., 2006) and PDB ID: 2FW3 (resolution: 2.50 Å) (Rufer et al., 2006). We used the work of Taylor et al. (2013) as a reference for the identification of some target proteins. Since the crystallized form of β -tubulin from *Haemonchus contortus* was not available in protein databases, we relied on the theoretical structure. Ions and ligands other than cofactors and water molecules were removed. The missing hydrogen atoms were added. We manually checked the residues of the protein for the completion of missing atoms and bonds. After all hydrogens were added, we optimized them, firstly using the "Clean Geometry" tool, followed by the Charm forcefield. After the optimized proteins were saved in pdb format using Discovery Studio 2020 Client, they were opened using ADT to add Gasteiger charges and then saved in pdbqt format. We referred to the procedure used by Yelekçi et al. (2013) as a guide for the preparation of proteins.

2.3. Homology modeling

We did research on the protein sequences known for *Syphacia obvelata* using the UniProt Knowledgebase (UniProtKB). Although the cytochrome c oxidase 1 (COX1) and COX2 proteins from the Mt genome are not known targets of anthelmintics, these were still selected because they are vital to oxyurida nematodes. Because the genome sequence of *S. obvelata* and the experimental crystal structure of the *Syphacia obvelata* COX1 (SoCOX1) and SoCOX2 proteins are unknown, we decided to use the homology modeling for their 3D structures. Another oxyurid nematode *Enterobius vermicularis* β -tubulin protein and *Caenorhabditis elegans* glucose transporter 1 (CeGLUT1) receptor also underwent modeled via homology modeling. We utilized the SWISS-MODEL (Waterhouse et al., 2018) and the Zhang lab I-TASSER web servers (Roy et al., 2010; Yang et al., 2015; Yang and Zhang, 2015) to develop a sequence overlap-based model. We selected the most appropriate 3D structure by considering Global Model Quality Estimating (GMQE) values and Qualitative Model Energy Analysis (QMEAN) values. For QMEAN, values below 4.0 indicate reliability, while for GMQE, the highest value between 0 and 1 indicates the most reliable estimated structure.

2.4. Docking process

Proteins, retrieved from the Protein Data Bank or whose 3D structure we predicted by homology modeling, were docked with ligands using AutoDock4.2 (Morris et al., 1998). We determined the size of the gridbox based on the size of the

ligand or the number of torsions. We chose the cofactor of the protein as the center, or in the absence of a cofactor, we took the native ligand in the protein into the center of the gridbox. For the beta-tubulin protein docking simulation, the ligand bound to the protein was chosen as the center. For the CPT enzyme, we referred to the coordinates given by Taylor et al. (2013). The atoms in the active site of the protein were free to move, while the other parts of the protein were rigid. For docking proteins bound with their natural ligands in their partially crystallized form, we took their natural ligands as reference. We set the dielectric constant to 10, the ionic strength to 0.145, the dimensions of the grid box to 60x60x60, and the grid point to 0.375 Å. Since the number of rotational bonds was less than 10, the maximum number of generations was set to 27 000 and the maximum number of extensions to 2 500 000. We performed the docking analysis using the Lamarkian Genetic Algorithm 4.2. We used AutoDock4.2 scoring functions to generate 10 different conformations for each ligand. After sorting by their free energy of binding, we analyzed the ligands with the highest scores for their binding site interactions using AutoDock Tools and Biovia Discovery Studio 2020 Client.

2.5. ADME prediction

We estimated the ADME (Absorption, Distribution, Metabolism, Excretion) properties of pseudoericiotin and ericiotin using the SwissADME web server (Daina et al., 2017) by comparing their ability to cross the blood brain barrier, gastrointestinal absorption and oral bioavailability.

The SwissADME web tool provides free access to a collection of rapid and also robust prediction models for physicochemical properties, pharmacokinetics, drug similarity, and medicinal chemistry relevance, including in-house authoritative methods such as BOILED-Egg, iLOGP, and Bioavailability Radar. Bioavailability radar is displayed for rapid assessment of drug similarity. Lipophilicity, molecular size, polarity, solubility, flexibility, and saturation properties are considered to generate this radar plot (Daina et al., 2017). The six properties in the bioavailability radar are the most basic criteria selected to show whether the physicochemical and pharmacokinetic values expected from a bioavailable compound are within reasonable limits.

According to bioavailability radar, a bioavailable compound should have a molecular weight (MW) between 150-200 g/mol, TPSA between 20-130 Å², lipophilicity (XLOGP3) between -0.7 and +5.0, carbon fraction in sp³ hybridization, a saturation marker, should not be less than 0.25 and solubility (log S) not more than 6 (Daina et al., 2017), water solubility score between 1-3 (1, highest solubility, 5, lowest solubility), number of rotatable bonds between 0-9 (Ritchie et al., 2011).

3. Results and Discussion

3.1. Evaluation of possible interactions between pseudoericiotin and rat carnitine palmitoyl transferase 2 (CPT 2)

One of the results of this study was that the inhibition constant of pseudoericiotin against rat CPT 2 (PDB ID: 2H4T) was 15.83 femtomolar. This result indicates that pseudoericiotin may be a very successful CPT 2 inhibitor. However,

pseudoericiotin can only be used to inform the design of a *de novo* drug candidate molecule, which in reality is not accessible in databases.

A study of the possible interactions of pseudoericiotin in the rat CPT 2 enzyme coded 2H4T pdb revealed a large number of interactions with the residues shown in Figure 2 A. Although most of these were apolar amino acids, polar hydrophilic residues such as serenyl and tyrosinyl were located very close to pseudoericiotin and TYR486 forms aromatic interactions. Figure 2 B shows that cyclic side chain residues such as PHE131 and PHE134 contribute to hydrogen bond formation rather than aromatic interactions.




Figure 2. Interactions between pseudoericiotin and the rat CPT 2 enzyme. **A)** Carbon atoms of pseudoericiotin are illustrated in blue, oxygen atoms in red, and the residues with which it interacts are represented by the yellow stick model. **B)** 2D representation of the interactions between pseudoericiotin and the rat CPT 2 enzyme (not shown in the figure because the AutoDock4.2 program does not display the abnormal bond formation in the defective molecule on the coordinate axis of the dlg file).

One of the most important factors in the interactions of pseudoericiotin was the chemical attractions emanating from the oxygen atoms on each ring of the ligand. As shown in Figure 2 B, residues LEU599, GLY600, PHE134, PHE131, SER88, and TYR486 formed hydrogen bonds using the oxygen atoms on the ligand. PHE134 formed two hydrogen bonds with the oxygen atoms of the ligand, one at a distance of 2.75 Å and the other at a distance of 3.29 Å, and SER588 formed a conventional hydrogen bond at a distance of 1.81 Å. PHE602 formed an aromatic interaction with one of the two rings in the center of the ligand and an amide-pi interaction with the other. PRO and ALA residues also formed pi-alkyl interactions with two different rings of the ligand. All rings of the ligand had at least one pi-alkyl interaction.

The hydrophobicity of the region formed by the residues around the pseudoericiotin was important because it directly affects the interactions of the ligand. Figure 3 below shows the hydrophobic and hydrophilic regions. The presence of some polar residues beyond the hydrophobic surface, caused by the side chains of amino acids such as alanine, valine, glycine, phenylalanine and leucine from the apolar residues surrounding one side of the ligand, caused these parts to be

hydrophilic. The surfaces shown in blue in Figure 3 represent the most hydrophilic regions, while the brown surfaces show the hydrophobic regions. The hydrophilic region at the top, where tyrosinyl and serinyl residues are located, stands out.




Figure 3. Representation of surface hydrophobicity around pseudoericiotin in the binding site of rat CPT 2 enzyme.

To compare the interactions, Figure 4 shows the position of true ericiotin in rat CPT 2 (2FW3) enzyme and the residues to which it binds. Figure 5 A and B show the different status of pseudoericiotin in the same enzyme.




Figure 4. Localization of true eriocitrin in rat CPT-2 enzyme (2FW3).





Figure 5. Interactions of pseudoeriocitrin and the CPT 2 enzyme (PDB code: 2FW3). **A)** 3D representation, **B)** 2D representation.

The video created to better illustrate the localization of pseudoeriocitrin in the enzyme CPT 2 (2FW3) is in Appendix 1.

Referring to Figure 6 A, which shows the surface of the CPT 2 enzyme and the possible entry site of the ligand, we predicted the cavity circled in orange to be the entry site for the binding site of the enzyme. Figure 6 B shows pseudoeriocitrin at the site where it binds in the enzyme for comparison.





Figure 6. CPT 2 enzyme (2FW3). **A)** In the representation of the enzyme surface, the cavity in the orange circle was presumed to be the entry cavity of pseudoeriocitrin into the enzyme. In the figure, blue regions represent hydrophilic regions and brown regions represent hydrophobic regions. **B)** In this version of the figure in A, shown without a surface, pseudoeriocitrin appears in the center, in the region of lowest energy, demonstrated with the stick model.

3.2. Evaluation and comparison of possible interactions between pseudoeriocitrin and *Ascaris suum* fumarate reductase (AsFR) and human fumarate reductase (hFR)

Since pseudoeriocitrin binds to AsFR at 512 pMKi, it also performed very well for inhibition for this enzyme. The position of pseudoeriocitrin on AsFR and hFR enzymes is shown in Figure 7 and Figure 8. A close look at the figures reveals the bi-oxygenated cyclic structure (ring in the middle of the molecule) that results from the abnormal bond formation and leads to the structure of pseudoeriocitrin. A short video to better understand the localization and interactions of pseudoeriocitrin in hFR can be seen in Appendix 2.




Figure 7. Pseudoeriocitrin, 6VAX, and 4YSX. The pseudoeriocitrin molecules are shown in their positioning within the enzymes AsFR (PDB code: 4YSX) and hFR (PDB code: 6VAX) so that their localization in both different proteins can be compared. AsFR is represented by an orange ribbon and FAD of AsFR by a purple stick model, hFR by a cream ribbon and FAD of hFR by a dark green stick model, pseudoeriocitrin docked to AsFR by a fuchsia ball-stick model, and pseudoeriocitrin docked to hFR by a turquoise ball-stick model.




Figure 8. Pseudoericiotin are shown in their positioning in hFR and AsFR, FADs are shown in purple and blue with a stick model, the isoalloxazine ring is very close to the pseudoericiotin; pseudoericiotin are shown in AsFR with a light-pink ball and stick model, and pseudoericiotin, represented by the turquoise ball-and-stick model, are shown at the docking points in the hFR where they are located at the lowest energy level.

Possible interactions of pseudoericiotin in AsFR are given in Figure 9 A and B. Hydrogen bond formation was predicted with five different residues. A pi-sigma bond with THR81 is also likely to occur.




Figure 2 consists of two panels. Panel (a) is a 2D interaction diagram showing the ligand (red sticks) interacting with various residues (green circles) via hydrogen bonds (dashed lines). The residues are labeled with their names and chain identifiers, such as PHE A:173, THR A:308, LEU A:306, and ARG A:340. Panel (b) is a 3D molecular docking model showing the ligand (red sticks) bound to the protein (yellow surface). Specific residues are labeled, including PHE173, ARG171, CYS191, GLY105, ALA102, and UNL1. Distances are indicated by dashed lines and numerical values, such as 2.15, 2.49, 2.27, 2.73, 2.62, 2.97, and 2.16.

Figure 10. Interactions of pseudoeriocitrin and hFR enzyme (6VAX) A) 2D representation shows the faulty bond that leads to the formation of pseudoeriocitrin. The oxygen atom opposite the LEU306 residue, represented by the purple ball in the figure, bonds with chromene to form an abnormal cyclic structure. B) 3D representation

11/18

The position of pseudoericiotin in CeGLUT1 and the interacting residues are shown in Figure 11 A and B. The docking simulations revealed that pseudoericiotin had a very good binding affinity. Although the structure of CeGLUT1 was predicted by homology modeling, we prepared the video in Appendix-3 prepared to show these interactions in more detail since the ΔG value for pseudoericiotin was -17.18 kcal/mol. The video shows pseudoericiotin with a purple ball and stick model, the protein with a pink ribbon and the residues with a thin stick model.




Figure 11. CeGLUT1 interactions with pseudoericiotin. **A)** 3D representation of pseudoericiotin represented by turquoise ball-and-stick model, interacting residues by thin stick model and protein by powdery pink strip ribbon model. **B)** 2D representation of pseudoericiotin and CeGLUT1 interactions (the program does not show real pseudoericiotin, the ligand in the figure looks like real ericiotin)

3.4. Pseudoericiotin and *Syphacia obvelata* cytochrome c oxidase 1 (SoCOX1) interactions

The ring structure formed by the formation of an extra bond between the chromene ring of pseudoericiotin and the rutinoside structure allowed pseudoericiotin to interact as shown in Figure 12 A and B. For a better understanding of the interactions with SoCOX1, the short video in Appendix-4 can be viewed.




Figure 12. Pseudoericiotin and SoCOX1 possible interactions. **A)** Pseudoericiotin is represented by a yellow ball and stick, the interacting residues are represented by a purple thin stick, the interactions are represented by dashed lines, and the secondary structure of the protein is represented by a cream-colored strip ribbon model. **B)** 2D representation clearly shows abnormally structured pseudoericiotin

As seen in Figure 12 A, the L-shaped structure formed by the rings of the ligand is strongly attracted by ALA62. In addition, the rhamnosyl ring of the rutinoside group at the other end of the ligand is attracted by the cyclic side groups of residues HIS39 and HIS40 through their aromatic interactions, while VAL107 on another α -helix is attracted to the same group from the opposite direction, so that the ligand adapts very well to its position. The most important chemical interactions shown in Figure 12 B are the hydrogen bonds formed by HIS39 and GLY104 residues with the oxygen atoms of the ligand. In addition, ALA62 formed six interactions with different points of the ligand. To classify these interactions shown with dashed lines in the figure based on their colors, the purple color represents the pi-sigma bond, the dark green short-distance lines represent hydrogen bonding, the pink lines represent pi-alkyl bonding and the light green long-distance lines represent polar interactions.

3.5. Docking results of pseudoericiotin with all proteins

We performed docking experiments with ligands three times. This was due to a structure change in the molecule, which was presumably caused by the optimization procedure. We later realized that the real reason was the presence of erroneous molecules in the FooDB database from which the ligand was taken. In the different molecular structure of pseudoericiotin, the formation of oxygen radicals and different geometry gave the molecule a very good score. Table 1 shows the docking results of pseudoericiotin. Docking procedure was repeated for pseudoericiotin two times. Different free binding energy values were obtained from dockings in the end of repeated computation.

Table 1. Docking results of Eriocitrin and Pseudoericiotin (PE) (ΔG values (kcal/mol))

	1OJ0	2H4T	4YSX	6VAX	SoCOX1	SoCOX2	6E7C	Ev Tub	CeGlut1	2FW3
Eriocitrin	+15.6	-8.43	-6.62	-12.87	-5.92	-3.92	+72.30	+104.9	-6.61	-9.72
PE (in first docking)	-3.21	-18.83	-13.84	-12.30		-8.70	+169.7	+118.6	-8.62	-12.17
PE (in second docking)	+3.67	-18.09	-12.67	-18.45	-16.93	-11.22	+49.1	+52.5	-17.18	-19.73

Table 2. Docking results of Eriocitrin and Pseudoeriocitrin (PE) (K_i values)

	1OJ0	2H4T	4YSX	6VAX	SoCOX1	SoCOX2	6E7C	Ev Tub	CeGlut1	2FW3
Eriocitrin	-	663,49 nM	14.13 uM	370,31 pM	45.64 uM	1.34 mM	-	-	14.24 uM	75.23 nM
PE (in first docking)	2270 uM	15.83 fM	71.76 pM	971,51 pM		417,7 nM	-	-	479,82 nM	1.19 nM
PE (in second docking)	-	55.00 fM	512 pM	29.86 fM	389,40 fM	59.4 nM	-	-	257,26 fM	3.45 fM

(PE in the table: Pseudoeriocitrin, fM: femtomolar, Ev Tub: *Enterobius vermicularis* β -tubulin)

Figure 13 A, B, and C show the SWISSADME results for this molecule.




Figure 13. SWISSADME result of pseudoeriocitrin. **A)** Molecular structure of pseudoeriocitrin, **B)** radar plot, **C)** ability to penetrate the blood-brain barrier.

Interestingly, this molecule was predicted in first looking that can penetrate the blood-brain barrier, is well absorbed in the gastrointestinal tract, and binds to some cytochrome enzymes that are not inhibited by eriocitrin. The original SWISSADME server printout showing these properties can be found in Appendix-5. In the second research for the same molecule, SWISSADME webserver did not accept to predict since the molecular weight is more than 500 g/mol. The most significant point was seen in Figure 13 A that pseudoeriocitrin is a multiradical. This radical structure is also related to toxicity and binding ability.

On the other hand, this molecule (pseudoeriocitrin) searched in ZincDatabase is not present in the database. The interactions associated with pseudoeriocitrin are intended to be used in the discovery of a new anthelmintic based on its

very favorable binding of free energies.

Amić et al. (2014) showed that a new bond can be formed in the morin molecule by calculating and comparing the enthalpy that enables the conformational change required to form an intramolecular bond. This new conformation of morin gives the molecule the ability to increase its radical scavenging activity while making it planar. Morin is also a flavone, and the prospective binding results in a planar extension of the flavone core, i.e., the formation of a ring parallel to the core plane. This is also the case for the flavone structure in our study. The bond formation between the flavone core and the rutinozide group increases the planar area consisting of cyclic structures. This allows the hydroxyl groups of the molecule to form a large number of hydrogen bonds with the protein, resulting in an increased inhibitory effect.

Brown et al. (2000) predicted that the inhibition of isoleucyl-t-RNA synthetase could be enhanced by some modifications of the inhibitor mupirocin. Indeed, the new inhibitors based on modified mupirocin combined with an amino acid side chain inhibited the enzyme isoleucyl-tRNA synthetase with 10 and 12 femtomolar K_D values, whereas the parent compound inhibited the same enzyme with 140 pM K_D value. When considered as a modified form of eriocitrin in the present study, pseudoeriocitrin appears to be much more favorable than eriocitrin in terms of efficacy. However, the fact that pseudoeriocitrin has a very high binding affinity for some proteins tested in this study suggests that it would be an extremely toxic molecule.

If Pseudoeriositrin's femtomolar inhibition value is due to a chemical reason, we think that this amazing inhibition ability may be due to the following properties:

1. The heterocyclic center structure has a planar geometry.
2. The core structure of the ligand (the combined cyclic structures in the center) is wide and consists of 4 rings.
3. Side chains attached to the core have hydroxyl groups or oxygen atoms.
4. Positioning of 3,4,5-trihydroxy-6-methyloxan-2-yl and 3,4-dihydroxyphenyl groups perpendicular to the core plane.
5. The center of the ligand is rigid in a wide area and the side groups are connected to the heterocyclic center via sigma bonds.

Its fact that radicalic oxygen atoms on pseudoeriocitrin are responsible for a number of hydrogen bonds, it should be researched whether normal double bonded oxygen atoms in spite of radicalic oxygen atoms could create the same inhibition effect.

4. Conclusion

It is worth further investigating whether this molecule can be formed during metabolism or in the laboratory. The formation of this molecule in the body, even for a short period of time, would inhibit different enzymes without covalent bonding at very lower ligand concentration, so it is of great importance to investigate this issue. On the other hand, new informations about the chemical nature of a magnificent inhibitor that has an ability to inhibit at femtomolar level were given in this study first time. These informations can be useful to design new potent inhibitors.

Acknowledgements

We would like to dedicate this paper to our esteemed Professor, deceased Prof. Dr. Metin Aktaş who always lives with his unforgettable benevolence and elegance.

Conflict of interest

The authors declare that there is no conflict of interest.

Research and Publication Ethics

The authors declare that this study complies with research and publication ethics.

References

- Amić, A., Marković, Z., Dimitrić Marković, J. M., Stepanić, V., Lučić, B., Amić, D. (2014). Towards an improved prediction of the free radical scavenging potency of flavonoids: the significance of double PCET mechanisms. *Food Chem*, 152, 578-585. doi: 10.1016/j.foodchem.2013.12.025.
- Brown, M. J., Mensah, L. M., Doyle, M. L., Broom, N. J., Osbourne, N., Forrest, A. K., Richardson, C.M., O'Hanlon, P. J., Pope, A. J. (2000). Rational design of femtomolar inhibitors of isoleucyl tRNA synthetase from a binding model for pseudomonas acid-A. *Biochemistry*, 39(20), 6003-6011. doi: 10.1021/bi000148v.
- Daina, A., Michielin, O., Zoete, V. (2017). SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules, *Sci Rep*, 7, 42717.
- Dassault Systèmes BIOVIA, Discovery Studio Modeling Environment, Release 2020, San Diego.
- Diab, K. A. E., Shafik, R. E., Yasuda, S. (2015). In vitro Antioxidant and Antiproliferative Activities of Novel Orange Peel Extract and its Fractions in Leukemia HL-60 Cells. *Asian Pac J Cancer Prev*, 16(16), 7053-7060.
- World Health Organization (WHO). (2012, January). *Accelerating Work to Overcome the Global Impact of Neglected Tropical Diseases: A Roadmap for Implementation*. Washington: WHO. 2012, 1-42. https://www.who.int/neglected_diseases/NTD_RoadMap_2012_Fullversion.pdf
- Ferreira, P. S., Manthey, J. A., Nery, M. S., Cesar, T. B. (2021). Pharmacokinetics and Biodistribution of Eriocitrin in Rats. *J Agric Food Chem*, 69(6), 1796-1805. doi: 10.1021/acs.jafc.0c04553.
- Giray, H., Keskinoglu, P. (2006). İlkokul öğrencilerinde *Enterobius vermicularis* varlığı ve etkileyen etmenler [The prevalence of *Enterobius vermicularis* in schoolchildren and affecting factors]. *Turkiye parazitoloji dergisi*, 30(2), 99–102. http://cms.galenos.com.tr/Uploads/Article_22736/TPD-30-99.pdf
- Guo, G., Shi, W., Shi, F., Gong, W., Li, F., Zhou, G., She, J. (2019). Anti-inflammatory effects of eriocitrin against the dextran sulfate sodium-induced experimental colitis in murine model. *J Biochem Mol Toxicol*, 33(11), e22400.
- Hsiao, Y. S., Jogl, G., Esser, V., Tong, L. (2006). Crystal structure of rat carnitine palmitoyltransferase II (CPT-II).

- Biochemical and biophysical research communications*, 346(3), 974–980. <https://doi.org/10.1016/j.bbrc.2006.06.006>
- Huey, R., Morris, G. M., Olson, A. J., Goodsell, D. S. A. (2007). Semiempirical Free Energy Force Field with Charge-Based Desolvation. *J Comput Chem*, 28, 1145-1152.
 - Inaoka, D. K., Shiba, T., Sato, D., Balogun, E. O., Sasaki, T., Nagahama, M., ... Harada, S. (2015). Structural Insights into the Molecular Design of Flutolanil Derivatives Targeted for Fumarate Respiration of Parasite Mitochondria. *International journal of molecular sciences*, 16(7), 15287–15308. <https://doi.org/10.3390/ijms160715287>
 - Inoue, T., Sugimoto, Y., Masuda, H., Kamei, C. (2002). Antiallergic effect of flavonoid glycosides obtained from *Mentha piperita*. *Biol Pharm Bull*, 25, 256-259.
 - Karaman, D. (2022). Prediction on the Anthelmintic Effects of Some Herbal Ligands and Their Derivatives with *In Silico* Molecular Modelling Method, Doctoral Thesis, Bursa Uludag University, 421p, Bursa, Türkiye.
 - Miyake, Y., Yamamoto, K., Osawa, T. (1997). Isolation of Eriocitrin (Eriodictyol 7-rutinoside) from Lemon Fruit (*Citrus limon* BURM. F.) and Its Antioxidative Activity. *Food Sci Technol Int Tokyo*, 3(1), 84-89.
 - Morris, G. M., Huey, R., Lindstrom, W., Sanner, M.F., Belew, R. K., Goodsell, D. S., Olson, A. J. (2009). Autodock4 and AutoDockTools4: Automated docking with selective receptor flexibility. *J Comput Chem*, 30, 2785–2791.
 - Morris, G. M., Goodsell, D. S., Halliday, R. S., Huey, R., Hart, W. E., Belew, R. K., Olson, A.J. (1998). Automated Docking Using a Lamarckian Genetic Algorithm and an Empirical Binding Free Energy Function. *J Comput Chem* 19, 1639-1662.
 - Ritchie, T. J., Ertl, P., Lewis, R. (2011). The graphical representation of ADME-related molecule properties for medicinal chemists. *Drug Discov Today*, 16, 65–72.
 - Robinson, M.W., McFerran, N., Trudgett, A., Houy, L, Fairweather, I. (2004). A possible model of benzimidazole binding to beta-tubulin disclosed by invoking an inter-domain movement. *Journal of Molecular Graphics and Modelling*, 23(3), 275-84. doi: 10.1016/j.jmgm.2004.08.001.
 - Roy, A., Kucukural, A., Zhang, Y. (2010). I-TASSER: a unified platform for automated protein structure and function prediction. *Nature Protocols*, 5, 725-738. https://zhanggroup.org/papers/2010_3.pdf
 - Rufer, A. C., Thoma, R., Benz, J., Stihle, M., Gsell, B., De Roo, E., ... Hennig, M. (2006). The crystal structure of carnitine palmitoyltransferase 2 and implications for diabetes treatment. *Structure (London, England: 1993)*, 14(4), 713–723. <https://doi.org/10.1016/j.str.2006.01.008>
 - Sharma, P., Maklashina, E., Cecchini, G., Iverson, T. M. (2020). The roles of SDHAF2 and dicarboxylate in covalent flavinylation of SDHA, the human complex II flavoprotein. *Proceedings of the National Academy of Sciences of the United States of America*, 117, 23548-23556. <https://doi.org/10.1073/pnas.2007391117>
 - Strelkauskas, A., Edwards, A., Fahnert, B., Pryor, G., Strelkauskas, J. (2015). *Microbiology: A Clinical Approach* (2. bs.). NY, USA: Garland Science. <https://doi.org/10.1201/9780429258701>
 - Taylor, C. M., Wang, Q, Rosa, B. A., Huang, S. C.-C., Powell, K., Schedl, T., ... Mitreva, M. (2013). Discovery of Anthelmintic Drug Targets and Drugs Using Chokepoints in Nematode Metabolic Pathways. *PLOS Pathogens*, 9(8), 1003505. doi:10.1371/journal.ppat.1003505
 - Ti, S. C., Alushin, G. M., Kapoor, T. M. (2018). Human β -Tubulin Isoforms Can Regulate Microtubule Protofilament Number and Stability. *Developmental cell*, 47(2), 175–190.e5. <https://doi.org/10.1016/j.devcel.2018.08.014>

- Waterhouse, A., Bertoni, M., Bienert, S., Studer, G., Tauriello, G., Gumienny, R., ... Schwede, T. (2018). SWISS-MODEL: homology modelling of protein structures and complexes. *Nucleic acids research*, 46(W1), W296–W303. <https://doi.org/10.1093/nar/gky427>
- Yang, J., Yan, R., Roy, A., Xu, D., Poisson, J., Zhang, Y. (2015). The I-TASSER Suite: Protein structure and function prediction. *Nature Methods*, 12, 7-8 https://zhanggroup.org/papers/2015_1.pdf
- Yang, J., Zhang, Y. (2015). I-TASSER server: new development for protein structure and function predictions. *Nucleic Acids Research*, 43, 174-181. doi: 10.1093/nar/gkv342
- Yelekçi K, Büyüktürk B, Kayrak N. (2013). In silico identification of novel and selective monoamine oxidase B inhibitors. *J Neural Transm (Vienna)*, 120(6), 853-858.